Toxic equivalency factors (TEFs) are assigned to dioxin-like chemicals based on relative potency (REP) values of individual adaptive and toxic responses compared to 2,3,7,. Agilent 4x44K oligonucleotide microarrays were used to examine the hepatic gene expression potency of 2,3,7,8-tetrachlorodibenzofuran (TCDF), relative to TCDD with complementary histopathology, TCDD and TCDF tissue level analysis, and ethoxyresorufin-O-deethylase (EROD) assay data. Immature ovariectomized C57BL/6 mice were gavaged with 0.03, 0.1, 0.3, 1, 3, 10, 30, or 100 mg/kg TCDD, the World Health Organization TEF-adjusted doses (10 3 TCDD dose) of TCDF (0.3, 1, 3, 10, 30, 100, or 300 mg/kg), or sesame oil vehicle and killed at 72 h. Two thousand two hundred eighty-eight and 1347 genes were differentially expressed (P1(t) > 0.90) at one or more doses by TCDD and TCDF, respectively. Automated doseresponse modeling (ToxResponse Modeler) identified a total of 1027 and 837 genes with either a sigmoidal, exponential, linear, Gaussian, or quadratic dose-response relationship 72 h after treatment in TCDD and TCDF, respectively. Two hundred seventy genes exhibited a sigmoidal TCDD-induced dose-response (ED 50s from 0.08 to 42.2 mg/kg) compared to only 179 sigmoidal responsive genes (ED 50s from 0.74 to 299.9 mg/kg) elicited by TCDF. Of the 1027 TCDD dose-responsive genes, 654 were not examined further due to the lack of a dose response elicited by TCDF. Of the 373 genes that exhibited a TCDD and TCDF dose response, REPs were calculated for the 83 genes that exhibited comparable sigmoidal curve shapes and slopes. The median REP for these 83 genes was 0.10, with a maximum REP of 0.56 and a minimum of 0.01. REPs of 0.04 were also calculated for EROD and increase in relative liver weight (RLW) at 72 h. Collectively, the lower number of TCDF-induced genes compared to TCDD and the 0.04 REPs for EROD activity and increased RLW are not consistent with the TEF of 0.10 for the hepatotoxicity of TCDF in C57BL/6 mice at 72 h.
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related chemicals, such as 2,3,7,8-tetrachlorodibenzofuran (TCDF), elicit a broad spectrum of species-specific biochemical and toxic effects. These chemicals are ubiquitous environmental contaminants that are by-products of waste combustion, herbicide production, and other industrial processes (Mason and Safe, 1986; Poland and Glover, 1973; Safe et al., 1982) . Many of these chemicals elicit their effects through binding and activation of the aryl hydrocarbon receptor (AhR), leading to nuclear translocation and heterodimerization with the AhR nuclear translocator. This complex mediates transcriptional changes through binding of the dioxin response elements within the regulatory regions of genes (Safe, 2001) .
Since exposure to TCDD and related chemicals occurs as complex mixtures, traditional methods for assessing the toxicity of single chemicals are inappropriate. Current practices consider all toxic dioxin-like congeners within a mixture to assess the overall toxicity of the mixture relative to TCDD, the most potent congener (Van den Berg et al., 1998 Berg et al., , 2006 . This toxic equivalency (TEQ) method is based on toxic equivalency factors (TEFs) assigned to each toxic congener. TEFs are agglomerative potency estimates relative to TCDD set by a World Health Organization (WHO) expert panel based on relative potency (REP) values (Van den Berg et al., 1998 . REPs are typically calculated by comparing the ED 50 values for a single response (e.g., increase in liver weight) induced by TCDD and dividing it by the ED 50 for the same response elicited by the congener of interest (Van den Berg et al., 2006) . TEFs are established by collectively considering the available REP data. The validity of the TEF/TEQ concept is based on the assumptions that responses must have parallel dose-response curves, exhibit additivity, and use the same mechanism of action (Safe, 1997; Starr et al., 1999) . The lack of quantitative measurements of uncertainty in the underlying data has also lead to questions regarding the accuracy of the estimated toxicity of a mixture of TCDD and related compounds (Starr et al., 1999) .
The current TEF for TCDF is set at 0.1, meaning 10 3 more TCDF is required to elicit the same effect as 1 3 TCDD. It is based on 36 in vivo and 19 in vitro REPs according to the OpenREP database with a scant amount of data obtained in the mouse (http://openrep.fst.msu.edu). The distribution of ''included'' REP values (obtained from the OpenREP database and the 2004 REP database; Haws et al., 2006) has a minimum of 0.006, a maximum of 0.63, and a median of 0.09, close to the WHO TEF (WHO TEFs are rounded to the nearest half-log 10 unit). To expand the available REP data in mice, we examined the hepatic gene expression potency of TCDF with complementary relative liver weight (RLW), histopathology, TCDD and TCDF tissue level, and ethoxyresorufin-O-deethylase (EROD) activity data.
MATERIALS AND METHODS
Animal husbandry. Intact immature female C57BL/6 mice, all having body weights (BWs) within 10% of the average BW, were obtained from Charles River Laboratories (Raleigh, NC) on postnatal day 25. This study used intact females as there was no interest in examining the potential (anti)estrogenic effects of TCDF. Mice were housed in polycarbonate cages containing cellulose fiber chips (Aspen Chip Laboratory Bedding, Northeastern Products, Warrensburg, NY) in a 23°C HEPA-filtered environment with 30-40% humidity and 12-h light/dark cycle (0700 h-1900 h). Animals were allowed free access to deionized water, fed ad libitum Harlan Tekad 22/5 Rodent Diet 8640 (Madison, WI), and acclimatized for 4 days prior to dosing. On the fourth day, animals were weighed and stock solutions of TCDD and TCDF (The Dow Chemical Company, Midland, MI) were diluted in sesame oil (Sigma, St Louis, MO) to achieve the desired dose based on average weight. All procedures were approved by the Michigan State University All-University Committee on Animal Use and Care.
Time course and dose-response studies. Doses were chosen based on (1) a published comprehensive TCDD time course and dose-response study and (2) the TEF for TCDF of 0.1 ( Van den Berg et al., 2006) . Mice were gavaged with 0.1 ml of vehicle or 0. 03, 0.1, 0.3, 1, 3, 10, 30, 100 lg/kg TCDD or 0.3, 1, 3, 10, 30, 100, 300 , 1000 lg/kg TCDF for 72 h. Treatments were staggered to ensure exposures were within 5% of the desired time. Doses were chosen to elicit moderate effects while avoiding overt toxicity in longer-term studies. Animals were killed by cervical dislocation, and tissue samples were collected, weighed, flash-frozen in liquid nitrogen, and stored at À80°C. The right lobe of the liver was fixed in 10% neutral buffered formalin (NBF, Sigma) for histological analysis.
Histological analysis. Sections through the center of the right middle lobe were processed sequentially in formalin, alcohol, butanol, xylene, and paraffin in a Tissue Tek VIP 5 vacuum infiltration processor (Torrance, CA). Tissues were then embedded in paraffin with a Miles Tissue Tek embedding center, after which paraffin blocks were sectioned at 6 lm with a rotary microtome. Sections were placed on glass microscope slides, dried, and stained with hematoxylin and eosin.
EROD assay. Hepatic microsomes were assayed for EROD activity in control, TCDD-and TCDF-treated samples (Moore et al, 2008) . Tissue was minced and homogenized using Tri-R Stir-R homogenizer in 0.05M Tris, 1.15% KCl, pH 7.5, and then centrifuged at 4°C, 10,000 3 g for 10 min. The supernatant was ultracentrifuged at 4°C, 100,000 3 g for 30 min. The microsomal pellets were resuspended in 0.01M EDTA, 1.15% KCl, pH 7.4, and recentrifuged at 100,000 3 g for 60 min. Final pellets were resuspended in a stabilizing buffer (20% glycerol, 0.1M KH 2 PO 4 , 1mM EDTA, and 1mM DTT, pH 7.25) and stored at À80°C. Resorufin production was measured kinetically at 590 nm on a 96-well plate (Costar, Corning, NY) using a Fluoroskan Ascent fluorometer (Thermo Fisher Scientific, Waltham, MA) and corresponding software (version 2.6). The assay was performed in 0.05M HEPES, pH 7.8 (Sigma-Aldrich, St Louis, MO), with 3.35mM 7-ethoxyresorufin (final assay concentration; Molecular Probes, Eugene, OR). Catalytic activity was initiated by addition of 0.3mM NADPH (final concentration; SigmaAldrich). Resorufin fluorescence was measured every 2 min. After 30 min, the assay was terminated by the addition of 36 lg fluorescamine in acetonitrile (Sigma-Aldrich). Protein was then measured at 460 nm using bovine serum albumin (Roche Applied Scientific, Indianapolis, IN) as a protein standard. Linear portions of each kinetic analysis were used to determine pmol of resorufin produced per minute and standardized to total protein (lg) to determine EROD activity (pmol/min/lg).
Quantification of TCDF and TCDD in liver tissues. Liver samples were processed in parallel with laboratory blanks and a reference or background sample at The Dow Chemical Company. Briefly, samples were weighed, spiked with 13 C 12 TCDD or TCDF surrogate, digested with hydrochloric acid containing 5% benzene:hexane solution, and then extracted. Extracts were cleaned, concentrated, and spiked with an injection standard. Analysis was performed on a high-resolution gas chromatography/high-resolution mass spectrometer (HRMS) using a Hewlett Packard 5890 series II GC interfaced to a VG 70SE HRMS (Hewlett Packard, CA). The HRMS was operated in the EI/SIR mode at 10,000 resolutions. A 60-m DB5 column (J &W Scientific, Folsom, CA) with an internal diameter of 0.25 mm and film thickness of 0.25 lm was employed. A splitless injection method with injection volume of 2 ll was employed.
RNA isolation. Frozen liver samples (~100 mg) were transferred to 1.3 ml of Trizol (Invitrogen, Carlsbad, CA) and homogenized in a Mixer Mill 300 tissue homogenizer (Retsch, Haan, Germany). Total RNA was isolated according to the manufacturer's protocol with an additional phenol:chloroform extraction. RNA was resuspended in RNA storage solution (Ambion Inc., Austin, TX), quantified (A 260 ) for concentration, and the purity determined by A 260 /A 280 ratio and by visual inspection of 1.0 lg on a denaturing gel electrophoresis.
Microarray experimental design. Agilent 4x44K oligonucleotide microarrays (Agilent Technologies, Santa Clara, CA) were used to evaluate changes in gene expression. All reagents and enzymes were provided by Agilent Technologies. Sample labeling and hybridization were performed as per the vendor's protocol. Assays were performed as a single channel (Cy3 dye), where one sample is assayed per array. Slides were scanned using a GenePix Personal 4000B microarray scanner (Molecular Devices, Union City, CA). Scanned images were analyzed for feature and background intensities using GenePix Pro 6.0 (Molecular Devices). All data were managed using the Toxicogenomic Information Management Systems dbZach (Burgoon and Zacharewski, 2007; Burgoon et al., 2006) .
Microarray data normalization and analysis. A semiparametric approach (Eckel et al., 2005) was employed for all data normalization. Empirical Bayes analysis was used to calculate posterior probabilities (P1(t) value) of activity on a per-gene and time point basis using the model-based t value (Eckel et al., 2004) . Normalization and empirical Bayes analysis were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC) and R version 2.8.1.
Quantitative real-time PCR. Quantitative real-time PCR (QRT-PCR) verification of microarray responses was performed as described previously . Briefly, 1.0 lg of total RNA was reverse transcribed by Superscript II using an anchored oligo-dT primer as described by the manufacturer (Invitrogen). The complementary DNA (cDNA) (1.0 ll) was used as a template in a 30 ll PCR reaction containing 0.1lM of forward and reverse gene-specific primers, 3mM MgCl 2 , 1.0mM dNTPs, 0.025 IU AmpliTaq Gold, and 13 SYBR Green PCR buffer (Applied Biosystems, Foster City, CA). Gene names, RefSeq accession numbers, forward and reverse 222 BURGOON ET AL.
primer sequences, and amplicon sizes are listed in Supplementary Table 1 . PCR amplification was conducted on an Applied Biosystems PRISM 7000 Sequence Detection System. cDNAs were quantified using a standard curve approach, and the copy number of each sample was standardized to housekeeping genes to control for differences in RNA loading, quality, and cDNA synthesis.
Dose-response modeling. A grid-enabled version of the ToxResponse
Modeler that operates on a multi-node computational grid was used for automated dose-response modeling by identifying the best linear, exponential, Gaussian, sigmoidal, or quadratic fits . REP values were calculated on a per-feature/per-gene basis using model-based ED 50 values:
Statistical analysis. Statistical analysis, unless otherwise defined, was performed using SAS v9.1. Data were analyzed using ANOVA followed by Dunnett's post hoc tests. Differences between treatment groups were considered significant when p < 0.05.
RESULTS

Organ and BWs
Changes in BW, liver weight, and cell morphology are characteristic rodent responses following exposure to TCDD and related compounds (Poland and Glover, 1973) . Significant (p < 0.05) dose-dependent increases in RLW were induced by TCDD and TCDF at 72 h (Fig. 1, Table 1 ). RLW ED 50 s were 1.40 and 34.5 lg/kg for TCDD and TCDF dose, respectively, with an estimated RLW REP of 0.04. Despite reports of wasting syndrome (Taylor et al., 1992) , mice in this study did not exhibit alterations in BW, consistent with other published studies Fletcher et al., 2001) .
Hepatic TCDD/TCDF Concentrations
Hepatic TCDD and TCDF levels were quantified to assess the TEF for TCDF in relation to RLW, histopathology and gene expression. Levels of both compounds significantly (p < 0.05) increased in a dose-dependent manner at doses as low as 0.1 lg/kg TCDD and 1 lg/kg TCDF at 72 h (Fig. 2) . TEQadjusted TCDF levels were lower than TCDD at all comparable doses, consistent with the differences in RLW effects, which may be due to hepatic clearance of TCDF (N'Jai et al., 2008).
Histopathology
TCDD and TCDF induced very slight to moderate cytoplasmic vacuolizations of hepatocytes at doses as low as 1 and 3 lg/kg, respectively (Table 2 ). In addition, there was COMPARATIVE TOXICOGENOMIC ASSESSMENT OF TCDF TEF a treatment-related increase in the number of animals with inflammatory cell infiltration accompanied by necrotic or degenerative hepatocytes at doses greater than 3 lg/kg TCDD and 1 lg/kg TCDF. With the exception of a minimal increase in severity at 100 lg/kg TCDD, these alterations did not worsen with higher doses (Table 2) .
Hepatic Gene Expression Response to TCDF and TCDD
Supplementary Figure 1 and Figures 3-5 describe the strategy used to create per-gene and aggregate gene expression REP values. It combines set theory and automated doseresponse modeling and incorporates the assumptions underlying the TEF concept. In part 1 (Fig. 3) , gene expression data were normalized (Eckel et al., 2005) and analyzed using an Empirical Bayes method (Eckel et al., 2004) to identify differentially expressed features. To be inclusive, a lower than usual P1(t) cutoff (P1(t) > 0.90) was used at the expense of higher false-positive/false discovery rates. TCDD elicited the differential expression of twice as many features when compared to TCDF (9994 vs. 5322, respectively). The union of these data sets was taken to identify all differentially expressed features to capture TCDD and corresponding TCDF dose-response data sets for the eventual calculation of genespecific REPs. This resulted in the identification of 11,541 features, of which only 1547 were unique to TCDF. Agilent controls and features missing data for at least one dose were removed and not considered further. Data from the automated dose-response analysis were then used to identify high-quality features, defined as those that had nonzero ratios (treated vs. control). The best linear, exponential, Gaussian, sigmoidal, or quadratic model was identified for each high-quality feature.
In part 2 (Fig. 4) , high-quality features were converted to unique genes. To be retained for further analysis, a response of greater than 1.5-fold relative to its corresponding time-matched vehicle control was required for at least one dose. This resulted in the loss of 65 and 79% of the TCDD and TCDF responsive genes, respectively, with TCDD still having approximately twice as many responsive genes compared to TCDF. Differentially expressed genes were also removed if their model-based ED 50 value was outside the experimental dose range. This resulted in 1027 and 837 TCDD and TCDF genes, respectively, that exhibited an expression change greater than 1.5-fold for at least one dose, a P1(t) > 0.90, and an ED 50 within the experimental dose range. An intersection of these genes identified only 373 genes that were differentially expressed following TCDD and TCDF treatment. This means that of the 1027 genes induced by TCDD, 654 were not represented in the TCDF set, and of the 837 TCDF genes, 464 were not represented in the TCDD set. Of the 373 genes, 360 had model-based REP values that were either real numbers (i.e., not an imaginary number [square root of À1]) or greater than zero. Of these, 270 TCDD and 179 TCDF genes exhibited sigmoidal dose-response curves. The intersection of these two sets resulted in 158 genes that exhibited a sigmoidal doseresponse following TCDD and TCDF treatment. Forty-one percent of the TCDD sigmoidal dose-responsive genes were not present in the TCDF set. Inflammation and necrosis at indicated doses (lg/kg) TCDF ne Figure 1) is divided into three parts for illustrative purposes. In the first part, differentially expressed features are identified using a P1(t) cutoff of 0.90 to maximize the possibility of identifying all differentially expressed genes, while sacrificing the false-positive and false discovery rates (which will be taken into account in later steps). Note that TCDD elicited the differential expression of twice as many features when compared to TCDF (9994 vs. 5322). The union of the two data sets was then taken to identify all differentially expressed features to have complete TCDD and TCDF dose-response data for the eventual calculation of gene-specific REPs. Agilent controls and features missing data for at least one dose were removed and not considered further. High-quality features, defined as those which have nonzero ratios (treated vs. control) for every dose, were retained.
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In part 3, the correlation coefficient between TCDD and TCDF modeled curves were used to abide by WHO TEF committee's assumptions regarding similar slopes and curve shapes (Fig. 5) . Eighty-three genes had correlation coefficients greater than 80%, our criteria for similar slopes and curve shapes, with REPs normally distributed and centered at 0.1 (7 genes having REP values between 0.01 and 0.03, 36 between 0.03 and 0.1, 33 between 0.1 and 0.3, and 7 from 0.3 to 1.0). No genes had a REP value greater than 1 or less than 0.01. The median REP value for the 83 genes was 0.1. QRT-PCR confirmed 5 of the 83 genes (Supplementary Figure 2) . A contour plot of the 86 TCDD and TCDF ED 50s identified the largest density of genes had a TCDD ED 50 < 12 lg/kg and a TCDF ED 50 < 150 lg/kg (Fig. 6) . The landscape plot also shows where each gene lies with respect to the REP values spanning from 0.01 to 10.
To historically anchor these results, the EROD assay was also performed. Whereas the gene expression REP for Cyp1a1 is 0.12, the corresponding EROD REP value was 0.04 as calculated using model-based ED 50 values from ToxResponse Modeler (Fig. 7) , consistent with EROD REPs (0.008-0.5) reported in OpenREP (http://openrep.fst.msu.edu).
TCDF did not elicit comparable qualitative and quantitative gene expression effects relative to TCDD at 72 h. This is consistent with the less severe inflammation and necrosis, and   FIG. 4 . Part 2 of the comprehensive dose-response analysis. High-quality differentially expressed features (P1(t) > 0.90) were converted to unique genes. Genes were retained for further consideration if its change in expression was greater than 1.5-fold for at least one dose. Approximately twice as many TCDD responsive genes were identified when compared to TCDF. Genes were examined further if its model-based ED 50 value, calculated by ToxResponse Modeler, was within the experimental dose range. The retained gene sets were intersected, resulting in 373 genes that exhibited an expression change greater than 1.5-fold for at least one dose, a P1(t) > 0.90, and an ED 50 value within the experimental dose range for both TCDD and TCDF. However, 654 genes within the TCDD set were absent from the TCDF set and 464 TCDF genes were not represented in the TCDD. Of the 373 genes, 360 had model-based REP values that were either real numbers (i.e., not an imaginary number (square root of À1)) or which were greater than zero. Of these, 270 TCDD and 179 TCDF genes exhibited sigmoidal dose-response curves. The intersection of these two sets resulted in 158 genes that exhibited a sigmoidal dose response following TCDD and TCDF treatment. Forty-one percent of the TCDD genes that exhibited a sigmoidal dose response were not present in the TCDF set.
FIG. 5.
Part 3 of the comprehensive dose-response analysis. In part 3, assumptions regarding similarities in the slopes and shapes of corresponding TCDD and TCDF dose-response curves were assessed by calculating the correlation coefficient of the curves. Eighty-three TCDD and TCDF curves with a correlation coefficient greater than 80% were considered similar in slope and shape and used to assess the distribution of REP values. COMPARATIVE TOXICOGENOMIC ASSESSMENT OF TCDF TEF the lower hepatic levels of TCDF. TCDD elicited the expression of 1027 genes with reasonable ED 50s compared to only 837 for TCDF with the intersection of these two gene sets resulting in an overlap of only 373 genes. In addition, TCDF did not elicit the differential expression of 654 TCDD-specific dose-responsive genes, and therefore, no REP could be calculated for these genes. Although TCDD did not elicit 464 TCDF-specific dose-responsive genes, further examination of the dose response in this study and reported time course data (N'Jai et al., 2008) indicate that the responses specifically elicited by TCDF typically included modest changes that were selected due to hard statistical cutoffs, as seen with PCB126 (Kopec et al., 2008) . For example, 340 of the 705 TCDDspecific gene expression responses exhibited a sigmoidal dose-response curve (48%) compared to only 127 of the 464 TCDF-specific responses (27%).
Many of the responsive genes have been previously characterized as responsive to TCDD Burgoon and Zacharewski, 2008) . No overrepresented functional categories were identified for genes with a calculated REP. A more thorough discussion of the association between differential gene expression and pathology has been previously described (Boverhof et al., , 2006 .
DISCUSSION
This study examined the dose-dependent hepatic gene expression effects of equipotent doses of TCDF and TCDD based on the WHO TEF of 0.1. As in our companion time course study (N'Jai et al., 2008) , complementary histopathology and hepatic tissue level analyses were also performed. Overall, the dose-response results are consistent with the conclusions from the time course study that despite both compounds eliciting comparable gene expression profiles, TCDF elicited fewer responses and was less potent than TCDD. More specifically, TCDD equivalent doses of TCDF (e.g., same TEQ doses) did not elicit comparable hepatic differential gene expression and histopathology in immature, ovariectomized C57BL/6 mice at 72 h. The 72-h time point was chosen for this study to determine the effect of TCDF elimination kinetics on REP values.
Consistent with the longer half-life of TCDD (10 days) compared to TCDF (2 days) (DeVito and Birnbaum, 1995) and the lower levels of hepatic TCDF accumulation in the time course study (N'Jai et al., 2008) , hepatic tissue levels of TCDF were also lower in the dose-response study, even when administered at the same TEQ doses. TCDF is reported to induce its own metabolic clearance via induction of Cyp1a1 Zwiernik et al., 2008) , and the lower tissue levels (expressed as TEQs) can be attributed to ligandspecific pharmacokinetic properties (DeVito and Birnbaum, 1995; Diliberto et al., 1995 Diliberto et al., , 2001 Hamm et al., 2003) . The lower tissue levels of TCDF are also in agreement with the reduced severity of hepatocellular necrosis and immune cell infiltration, and less severe vacuolization. Associations between differential gene expression (e.g., lipid metabolism and transport; immune response) and elicited liver histopathology have been previously described (Boverhof et al., , 2006 . This suggests that ligand-specific pharmacokinetics and disposition contribute to differences in relative potencies across end points and that hepatic TCDD and TCDF tissue levels are important factors in phenotypically anchoring gene expression. An even larger reduced potency of TCDF would be expected at environmentally relevant exposures.
In addition to more modest histopathological effects, TCDF also elicited fewer and less potent gene expression changes compared to TCDD. More specifically, TCDD elicited the differential expression of 1027 genes compared to only 837 for TCDF. Furthermore, to be consistent with preferred TEQ practice Van den Berg et al., 2006) , gene expression REPs were limited to 83 genes that exhibited sigmoidal dose-response curves with similar slopes and shapes for TCDD and TCDF. Although the exclusion of genes exhibiting exponential, quadratic, and linear dose-response relationships (where lack of an asymptotic response makes calculation of an ED 50 value impossible) were significant attrition factors, weak induction (<1.5-fold) or no response elicited by TCDF also reduced the number of genes that could be considered. The exclusion of nonsigmoidal dose-response data is likely to become more prevalent as studies focus on environmentally relevant exposures and move away from highdose studies. Alternatively, REPs calculated using model-based points of departure , lowest observed effect levels, no observed adverse effect levels, or other methods may also considered (Van den Berg et al., 2006) .
Limiting our approach, as well as other comparable strategies (Thomas et al., 2007) , is the association of gene FIG. 7 . Dose-response induction of EROD activity by TCDD and TCDF. ED 50 values for TCDD and TCDF were determined to be 1.47 and 40.51 lg/kg, respectively, yielding a REP of 0.04. expression REPs to specific events to distinguish adaptive effects from toxic responses. Ideally, REPs would be agglomerative and based on all gene, protein and metabolite REPs involved in a pathway that could be associated with toxicity, while not considering REPs for adaptive responses. However, this would require not only the integration of toxicity data with functional annotation for differentially expressed genes, proteins, and metabolites but also the elucidation of the mechanisms involved in eliciting the toxic response. Nevertheless, this study increases the available REP data for TCDF using the immature ovariectomized C57BL/6 mice and provides further evidence that the equipotent doses of TCDF elicit weaker responses when compared to TCDD due to differences in pharmacokinetics.
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